We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+15.91%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$6.19M
(+2.9%)
Cap. Flow
-$26.1M
Cap. Flow
% of AUM
-12.07%
Top 10 Holdings %
Top 10 Hldgs %
57.5%
Holding
62
New
15
Increased
10
Reduced
17
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$7.7M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$6.63M |
| 3 |
Prothena Corp
PRTA
|
+$6.46M |
| 4 |
Organogenesis Holdings
ORGO
|
+$6.4M |
| 5 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
+$4.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$13.5M |
| 2 |
uniQure
QURE
|
+$4.96M |
| 3 |
Centene
CNC
|
+$4.95M |
| 4 |
AC Immune
ACIU
|
+$4.66M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$3.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.72% |
| 2 | Miscellaneous | 8.38% |
| 3 | Technology | 3.62% |
| 4 | Energy | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $27.5M | 12.69% |
175,738
+59,938
| +52% | +$7.7M |
|
|
2
Organogenesis Holdings
ORGO
$224M
| $15.2M | 7.04% |
2,023,441
+1,346,888
| +199% | +$6.4M |
|
|
3
Prothena Corp
PRTA
$479M
| $13.1M | 6.06% |
1,091,202
+546,007
| +100% | +$6.46M |
|
4
Cue Biopharma
CUE
$203M
| $11.3M | 5.24% |
30,219
+6,554
| +28% | +$2.62M |
|
|
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.2M | 5.17% |
145,700
-17,357
| -11% | -$1.3M |
|
6
Bristol-Myers Squibb
BMY
$136B
| $10.5M | 4.84% |
169,000
-16,500
| -9% | -$1.01M |
|
7
Baxter International
BAX
$13.5B
| $9.71M | 4.49% |
121,075
-925
| -0.8% | -$73.3K |
|
8
Encompass Health
EHC
$11.9B
| $9.45M | 4.37% |
143,675
+8,018
| +6% | +$472K |
|
9
Cigna
CI
$73.7B
| $8.62M | 3.98% |
41,418
-5,582
| -12% | -$1.09M |
|
|
CHNG
10
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $7.84M | 3.62% |
420,514
-203,686
| -33% | -$3.35M |
|
11
Aurinia Pharmaceuticals
AUPH
$2.17B
| $7.04M | 3.25% |
508,715
-86,285
| -15% | -$1.26M |
|
|
12
Vertex Pharmaceuticals
VRTX
$137B
| $6.83M | 3.16% |
+28,900
| New | +$6.63M |
|
|
ALBO
13
DELISTED
Albireo Pharma Inc
ALBO
| $6.56M | 3.03% |
174,791
+52,291
| +43% | +$1.9M |
|
|
ALXN
14
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $6.25M | 2.89% |
40,000
+6,000
| +18% | +$771K |
|
15
Aldeyra Therapeutics
ALDX
$89.9M
| $6.23M | 2.88% |
908,488
-183,512
| -17% | -$1.29M |
|
16
MeiraGTx Holdings
MGTX
$1.33B
| $5.77M | 2.67% |
381,119
-9,980
| -3% | -$141K |
|
17
Zimmer Biomet
ZBH
$19.2B
| $5.47M | 2.53% |
36,566
-13,492
| -27% | -$1.91M |
|
|
TVRD
18
Tvardi Therapeutics
TVRD
$24.3M
| $4.45M | 2.06% |
8,168
+3,317
| +68% | +$1.74M |
|
|
MTCR
19
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $4.43M | 2.05% |
563,303
+44,507
| +9% | +$408K |
|
|
INOV
20
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $4.2M | 1.94% |
+230,877
| New | +$4.93M |
|
|
APTO
21
DELISTED
Aptose Biosciences, Inc.
APTO
| $3.61M | 1.67% |
1,833
-698
| -28% | -$1.64M |
|
22
PUT
Twist Bioscience
TWST
$8.87B
| $3.53M | 1.63% |
+25,000
| New | +$2.77M |
|
|
MGLN
23
DELISTED
Magellan Health Services, Inc.
MGLN
| $3.15M | 1.45% |
+37,969
| New | +$3M |
|
|
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
| $2.99M | 1.38% |
149,522
-31,402
| -17% | -$642K |
|
|
25
Centene
CNC
$32B
| $2.4M | 1.11% |
40,000
-77,935
| -66% | -$4.95M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2020 Portfolio in Review
As of Q4 2020, Prosight Management held 62 positions worth $216M, up 2.9% from $210M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Prosight Management withdrew a net $26.1M in Q4 2020, closing 20 positions and reducing 17 holdings. Its most notable exit was Iovance Biotherapeutics, an estimated $3.97M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Prosight Management opened a new position in Vertex Pharmaceuticals worth $6.83M.
- Prosight Management's largest Q4 2020 buy was Vertex Pharmaceuticals: 28,900 shares worth $6.83M.
- Prosight Management added most to Alexion Pharmaceuticals in Q4 2020, an estimated $7.7M increase.
- Prosight Management's biggest Q4 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $13.5M.
- Prosight Management fully exited Iovance Biotherapeutics in Q4 2020, selling an estimated $3.97M.
- Prosight Management's ten largest holdings make up 57% of its $216M portfolio in Q4 2020.
- Prosight Management opened 15 new positions and closed 20 in Q4 2020.
- Prosight Management's portfolio value rose 2.9% quarter-over-quarter to $216M.
Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.